Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq1Nk42KM7:TR?= M2D5bVEuPCCm NYTDTIl{TE2VTx?= NHzIOnhmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIITy[YF1dWWwdDD3bZRpKHSjbX;4bYZmdg>? M4DRZlI2PDlyM{iz
H1703 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7vNk42KM7:TR?= NFHTN4wyNTRiZB?= MortSG1UVw>? M1\BToVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv M2ns[VI2PDlyM{iz
HUVECs NETTeIhEgXSxdH;4bYNqfHliQYPzZZk> Mn33NVAxKG6P MWOyOEBp NFnMXIFifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NHy1OJozPTR3MEG4Oi=>
APRE-19 MWnBdI9xfG:|aYOgRZN{[Xl? MlrNOUDPxE1? NG\JfYwzPCCq MoDtZYJwdGm|aHXzJGZNYi2vZXTpZZRm\CCycn:td5Vzfmm4YXyvZY51cS2jcH;weI9{cXNiYXP0bZZqfHl? NET6boczPTN{OU[xOy=>
MDA-MB-231 NHHOS2xCeG:ydH;zbZMhSXO|YYm= M4T5PVHDqM7:TdMg NUX1U2N4PDhiaB?= NIr6cpNFVVOR M{jId4Rm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEB1emWjdHXkJJdqfGhiMkWg{txOKG:oIF[xJI9zKEZ{INMg NGX0R2gzPTNyMEmzNi=>
MCF7 M{LTNGZ2dmO2aX;uJGF{e2G7 MUWxNFAhdk1? NInISGEzPCCq MYflcIlucW6jdHXzJGUzNWmwZIXj[YQhSVKHLVz1Z{Bi[3Srdnn0fS=> NFiwVW4zPTF5MkW1Oy=>
HT-29  MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrYRYMyNjYEoNM1US=> NUHyNWVXQTZiaB?= NXfpRYhU\GWlcnXhd4V{KGOnbHyg[5Jwf3SqIIfobYNpKGOjbjDi[UBqdmirYnn0[YQh[nliS2nORS=> M3\4elI2ODF{MUKz
MO59K  MkHaR5l1d3SxeHnjbZR6KEG|c3H5 Mlm1OeKh|ryP MVm3JIQ> NGPvN4VFVVOR MXLlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? M2HDSFI1QTV|NU[x
MO59J NULGdY9vS3m2b4TvfIlkcXS7IFHzd4F6 NHTHTGo2yqEQvF2= M3izb|ch\A>? NV;4d4M6TE2VTx?= MUPlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NWn1NIt{OjR7NUO1OlE>
MO59K  MmXwRZBweHSxc3nzJGF{e2G7 NV7CRVFvOTBizszN MlLlNlQhcA>? M13RbWROW09? NUO1bWQ{cW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw M3e1RVI1QTV|NU[x
MO59J MkW5RZBweHSxc3nzJGF{e2G7 M3u3elExKM7:TR?= MYKyOEBp NFLPUIdFVVOR M1L2Wolv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? NYi3e4kxOjR7NUO1OlE>
HepG2 M1TRVGZ2dmO2aX;uJGF{e2G7 NEPOcXoyODBibl2= M4nne|AvPSCq MVjEUXNQ MXHicI9kc3NiTVGtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;u M1Thb|I1QDZ|M{Ww
A549  M{TlWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD5SpUyOyEEtV5CpC=> NVnrSmlqOiCq NVjsZVc3e3WycILld5NmeyCyZX3leJJmgGWmLXnu[JVk\WRiQXv0JIFv\CCJU1uz{tIh[WO2aY\heIlwdixiUz3wbIF{\SCjcoLld5QtKGOnbHygZZBweHSxc3nzJIFv\CClYYPwZZNmNTNiYXP0bZZifGmxbh?= NFHHe3AzPDh2N{i2Ny=>
A549  NF\vbGRHfW6ldHnvckBCe3OjeR?= NV;z[ZJ6OTEEoN88ceKh NVPF[GQ3OTZiaB?= MnrzSG1UVw>? NXTQOo95dW:mdXzheIV{KHSqZTDJRXYhemWybHnjZZRqd25iYX7kJINifXOnczDy[ZRmdnSrb36gc4YhVlBiaX6geIhmKG63Y3zleZMv MoHwNlQ5ODJzMUG=
SK-N-LO MYfGeY5kfGmxbjDBd5NigQ>? M{PCSVExOCCwTR?= NGrhSZUxNjViaB?= NIXSV5Vl\WO{ZXHz[ZMhfGinIIP0bY12dGGwdDDl[oZm[3S|IH;mJI1wenCqaX7lJI9vKEGtdDDwbI9{eGixconsZZRqd25? NXHYRXFnOjR4NUS2NFY>
HL-60 NFn5WGJHfW6ldHnvckBCe3OjeR?= M3nNdlAvOcLizszN NWjVZWFOPzJiaB?= M2GxeoJtd2OtczDkZZNifGmwaXKtbY5lfWOnZDDj[YxtKGSrZn\ldoVvfGmjdHnvci=> MmLiNlQ3ODd{N{O=
HepG2  NXjQWnprTnWwY4Tpc44hSXO|YYm= NUT5Umt[OjByIH7N MWiwMlUhcA>? M{KzO4F1fGWwdXH0[ZMhTm:6TzDwbI9{eGixconsZZRqd25? NI\Cb24zPDV|NUG5Ni=>
H520 NEW5dFBHfW6ldHnvckBCe3OjeR?= MV:xNOKh|ryP M2\URlEhcA>? M1vOSWROW09? Mnzs[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz M1HOZ|I1PDR5OUO1
H1975 M1nCOGZ2dmO2aX;uJGF{e2G7 M3XWT|ExyqEQvF2= MkD0NUBp M17vPGROW09? M4nTd4Rm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> MnfFNlQ1PDd7M{W=
MG-63 MVnBdI9xfG:|aYOgRZN{[Xl? MYqxNEDDvU1? NHfwRZoyOiCq MUflcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> M3K5OFI1OzV6M{Cx
5637 M1KzcGFxd3C2b4Ppd{BCe3OjeR?= MmPKNVDDqM7:TR?= M2nTZlQxKG2rbh?= M3XnPZJmfmW{c3XzJJAzOVeDRkGg[ZhxemW|c3nvckwhS0SNIHX4dJJme3Orb36sJIFv\CClZXzsJIlvcGmkaYTpc44hcW6mdXPl[EBjgSCodXPvbYRidg>? MXuyOFM{Ozh4OB?=
HEK-293 NVX6b3ZZTnWwY4Tpc44hSXO|YYm= MVSxOVBvVQ>? MXuxOkBp M2XrcWROW09? NH3kOXRl\WO{ZXHz[ZMhS1KWIHHjeIl3cXS7 M3W1dFI1OzJ2M{[2
SW480  NV3DbJdJTnWwY4Tpc44hSXO|YYm= NUfiPGZPOTVybl2= Mn\sNlAhcA>? M{HqdWROW09? NF7H[IZz\WS3Y3XzJINmdGy3bHHyJIFk[3WvdXzheIlwdiCxZjFOtk1k[XSnbnnu NGXHSYMzPDN{NEO2Oi=>
HepG2 MmTaSpVv[3Srb36gRZN{[Xl? MojhNVAxKG6P Mke4NlQhcA>? NIDaW4xifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= NFrWclczPDJ7N{WxNC=>
HCT 116  M1X1TGZ2dmO2aX;uJGF{e2G7 MlnQNVAxKG6P Mmr3NlQhcA>? MXPheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? MUeyOFI6PzVzMB?=
BEL/FU Mmr3SpVv[3Srb36gRZN{[Xl? Ml;2NUBuVQ>? M1rQWlI1KGh? MnKw[IVkemWjc3XzJJBzd3SnaX6gcIV3\Wy|IH;mJJRp\SCSSUPLM2FsfCCyYYToe4F6 M1O2PFI1OjN{MEm5
Huh7  M{\TbWZ2dmO2aX;uJGF{e2G7 NG\JSms{yqEQvF2= NGHCSlcyKGh? M{HjcZJm\HWlZYOgeIhmKH[rcoXzJIVvfHK7IHnueI8hfGinIHPlcIx{ MV[yOFE5PDF7Nh?=
A-375 NE\m[opCeG:ydH;zbZMhSXO|YYm= MXS0M|gh|ryP NV7YeII6OjRiaB?= NUi1TWxE\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M4naXlI1OTF|MUez
A-375-TS  M2PCcWFxd3C2b4Ppd{BCe3OjeR?= NUnFO3E3PC96IN88US=> NX3ONmk{OjRiaB?= MVrlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MmDtNlQyOTNzN{O=
Mel-HO MmLnRZBweHSxc3nzJGF{e2G7 MoLnOE85KM7:TR?= MUGyOEBp M{XXdYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NHzMfmEzPDFzM{G3Ny=>
Mel-HO-TS MWrBdI9xfG:|aYOgRZN{[Xl? MYK0M|gh|ryP M{n2cFI1KGh? NGDmSoJmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MlW3NlQyOTNzN{O=
MeWo NVfkcGI2SXCxcITvd4l{KEG|c3H5 MnvZOE85KM7:TR?= M1fBTlI1KGh? MnHG[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NGXuR2wzPDFzM{G3Ny=>
Mel-2a MYPBdI9xfG:|aYOgRZN{[Xl? M4jNcVQwQCEQvF2= M3;R[FI1KGh? NIjTdoJmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NHPScI8zPDFzM{G3Ny=>
MDA-MB-231 M4PIR2Z2dmO2aX;uJGF{e2G7 MWOw5qCUPDByIH7N M1TVXVQhcA>? M2OwbZN2eHC{ZYPz[ZMhSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2HGeFIzQTB4MkW5
MDA-MB-231 M1zS[WZ2dmO2aX;uJGF{e2G7 MWC0NFAhdk1? NInzTJc1KGh? NGX3[XNl\WO{ZXHz[ZMhVU2SLUmgZY5lKEmOLUigdJJwfGWrbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MX:yNlkxPjJ3OR?=
Jurkat NIT4WppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[wNE4zPS1zLkK1JO69VQ>? M2L0RVI1NzR6IHi= MYTEUXNQ NYDsd5FZcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= Ml\uNVk4PTdzOEW=
Namalwa MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTqUVYxNjJ3LUGuNlUh|ryP NIPE[IEzPC92ODDo MXPEUXNQ NHjlUWVqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MlvVNVk4PTdzOEW=
Jurkat NWHZR21nSXCxcITvd4l{KEG|c3H5 NYfo[4JxOC5{NT2xMlI2KM7:TR?= NY\LUFJGOjRxNEigbC=> M1;ObGROW09? M1\4VYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> M3rHblE6PzV5MUi1
Namalwa MlTjRZBweHSxc3nzJGF{e2G7 NH2xW4MxNjJ3LUGuNlUh|ryP MlqxNlQwPDhiaB?= M17rd2ROW09? MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NUW2ZVhuOTl5NUexPFU>
K562 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrNSGEzPCCq MVXJR|UxRTJ3wsGwMlE1KG6P MknINVk3PjJ|NkG=
SW1990 MVnGeY5kfGmxbjDBd5NigQ>? NF3PO5YxNjBzLUGg{txO MnzENUBp MY\pcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NUfCS|hNOTl2NkmwNlA>
RT112  M{HkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNOKh|ryP MoPVNlQhcA>? MX3EUXNQ M{\pe4Rm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ MVWxPFc5Pzh|Mh?=
MHG-U1 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPUNVDDqM7:TR?= NFjWfoUzPCCq MXnEUXNQ MYrk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gS|IwVSClZXzsdy=> NUHaW|BqOTh5OEe4N|I>
SMMC-7721 MnS2RZBweHSxc3nzJGF{e2G7 Mm\kNlAxyqCwTR?= MVuyOEBp MV;pcoNz\WG|ZYOgR2hZNWmwZIXj[YQh[XCxcITvd4l{ NYrlUoQ4OTd3NUexPVE>
SMMC-7721 NF3iWpZHfW6ldHnvckBCe3OjeR?= MX2yNFDDqG6P NFzKUYwzPCCq MV;1dE1z\We3bHH0[ZMh|rJzLETHWFEh\XiycnXzd4lwdg>? M4DDPVE4PTV5MUmx
HeLa MljoSpVv[3Srb36gRZN{[Xl? NWHsdVBuOTBywrDuUeKh NEHiPXcyKGh? MoHGZYx1\XK|IITo[UBud3KyaH;sc4d6KG:oIITo[UB1emGwc3\ldpJqdiC{ZXP5Z4xqdmdiY3;tdIFzfG2nboS= Moe5NVY5QTB7MUW=
MRC5VI NXT5R4J[TnWwY4Tpc44hSXO|YYm= NUfX[HJIOTJwNTDtUS=> NE\hdlcxNjViaB?= Mkm3SG1UVw>? MWjhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> MnfqNVYzOjd|OUS=
AT5BIVA MYTGeY5kfGmxbjDBd5NigQ>? NVXpPFRSOTJwNTDtUS=> NXLqZlFwOC53IHi= MULEUXNQ NH;RSYVi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MWOxOlIzPzN7NB?=
M059J MULGeY5kfGmxbjDBd5NigQ>? M3SxNlEzNjVibV2= M3[zXFAvPSCq NXvwW5RqTE2VTx?= MV;hZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> MkewNVYzOjd|OUS=
HeLa NInNc3pHfW6ldHnvckBCe3OjeR?= NF3xfIEyOi53IH3N NHvjU|YxNjViaB?= NYPrdpd5TE2VTx?= NF6zUnZi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? NXvHWpoxOTZ{MkezPVQ>
N2a NHLDe4NCeG:ydH;zbZMhSXO|YYm= MU[wMlEuOTBizszN NGnC[mYzKGh? M1PDbolv\HWlZYOg[IVkemWjc3XkJINmdGxidnnhZoltcXS7IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ NIDWPXQyPTh2Mke2Oy=>
Jurkat  M{HWOWtqdmG|ZTDBd5NigQ>? M1zRSWlEPTBib3[gNlQhdk1? M3jGW|E2PjZ2NUG5

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5%DMSO+corn oil
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID